[{"id":"c19d8f37-59b1-415c-8978-46cc1e9175a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05308654","created_at":"2022-04-04T14:52:53.458Z","updated_at":"2024-07-02T16:35:22.296Z","phase":"Phase 1","brief_title":"A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets","source_id_and_acronym":"NCT05308654","lead_sponsor":"AbbVie","biomarkers":" BCL2","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Darzalex (daratumumab) • dexamethasone • surzetoclax (ABBV-453)"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 05/17/2022","start_date":" 05/17/2022","primary_txt":" Primary completion: 08/28/2026","primary_completion_date":" 08/28/2026","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2024-01-25"}]